Cite

HARVARD Citation

    Tu, Y. et al. (n.d.). IDDF2022-ABS-0103 A selective class I HDAC inhibitor recovers intratumoral interferon signaling to overcome immune-checkpoint blockade resistance in hepatocellular carcinoma. Gut. p. A18. [Online]. 
  
Back to record